Bayer

A global life-science company built on two core competencies, health care and agriculture, operating under the stated mission 'Health for all, Hunger for none'. Its own framing is that products and services are designed around the world's greatest challenges and most fundamental human needs - access to medicine and access to nutrition. The health care side is a research-driven pharmaceutical and consumer health operation: the company's own newsroom describes regulatory filings for additional indications of its cardiorenal drug Kerendia in international markets, indicating an active prescription pipeline managed market by market rather than a single-territory business. The agriculture side is a crop science operation spanning seed genetics and crop protection; recent activity includes a licensing agreement with the French seed group RAGT and a stated plan to move to broad hybrid wheat commercialization by the early 2030s, which places germplasm development, trait licensing and multi-year varietal commercialization inside its capability set. The product portfolio is presented as a broad A-to-Z catalog of consumer-recognized brands that the corporate brand has been built on, spanning both divisions. Geographic reach is worldwide, with market-specific communications separated by territory (press material is explicitly scoped in or out of U.S. and U.K. distribution) and an investor-facing reporting calendar on the standard quarterly cadence - half-year financial reports, Q3 quarterly statements and accompanying media updates - consistent with a publicly listed group. For a supplier directory the relevant profile is a large-scale, publicly traded manufacturer with pharmaceutical R&D, consumer health products, and seed and crop-protection inputs, supported by internal regulatory-affairs, licensing and multi-market commercialization functions. Nothing on the page indicates contract manufacturing or private-label service work; the business is presented as a branded principal in both healthcare and agricultural inputs.